Xiamen Amoytop Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	3,805	3,680	2,809	2,093	1,517	1,123
Other Revenue	15.19	15.19	7.75	7.74	10	9.51
Revenue	3,820	3,696	2,817	2,100	1,527	1,132
Revenue Growth (YoY)	29.70%	31.18%	34.13%	37.55%	34.86%	42.61%
Cost of Revenue	298.16	259.99	183.51	140.2	171.01	126.99
Gross Profit	3,522	3,436	2,634	1,960	1,356	1,005
Selling, General & Admin	1,889	1,815	1,392	1,060	841.02	700.65
Research & Development	414.92	388.03	294.71	228.52	148.58	79.74
Other Operating Expenses	23.97	18.68	13.3	10.95	7.64	5.55
Operating Expenses	2,328	2,222	1,703	1,300	995.83	783.6
Operating Income	1,194	1,214	930.33	659.88	360.06	221.64
Interest Expense	-1.42	-1.42	-0.45	-0.51	-0.62	-1.07
Interest & Investment Income	10.95	10.64	6.99	10.17	8.09	7.84
Currency Exchange Gain (Loss)	-0.38	-0.38	-0.12	-1.03	0.48	-0.47
Other Non Operating Income (Expenses)	-11.33	-0.25	-0.09	-0.39	-0.25	-0.24
EBT Excluding Unusual Items	1,191	1,222	936.67	668.13	367.77	227.69
Gain (Loss) on Sale of Investments	3.41	3.45	0.88	2.65	0.4	1.8
Gain (Loss) on Sale of Assets	-0.37	-0.99	-0.03	-0.87	0.03	-1.8
Asset Writedown	-	-	-	-12.76	-	-
Other Unusual Items	-49.28	-49.28	-6.5	-16.49	-12.27	-12.4
Pretax Income	1,145	1,175	931.03	640.65	355.93	215.29
Income Tax Expense	131.6	144.14	103.42	85.21	68.91	34.09
Net Income	1,014	1,031	827.6	555.45	287.02	181.2
Net Income to Common	1,014	1,031	827.6	555.45	287.02	181.2
Net Income Growth	15.06%	24.61%	49.00%	93.52%	58.40%	55.44%
Shares Outstanding (Basic)	409	408	408	405	404	403
Shares Outstanding (Diluted)	411	409	408	405	404	403
Shares Change (YoY)	0.64%	0.38%	0.56%	0.29%	0.39%	0.18%
EPS (Basic)	2.48	2.53	2.03	1.37	0.71	0.45
EPS (Diluted)	2.47	2.52	2.03	1.37	0.71	0.45
EPS Growth	14.33%	24.14%	48.18%	92.96%	57.78%	55.17%
Free Cash Flow	385.72	473.23	179.28	223.64	143.99	43.85
Free Cash Flow Per Share	0.94	1.16	0.44	0.55	0.36	0.11
Dividend Per Share	0.620	0.620	0.620	0.410	0.213	0.100
Dividend Growth	-	-	51.22%	92.49%	113.00%	100.00%
Gross Margin	92.20%	92.97%	93.49%	93.33%	88.80%	88.78%
Operating Margin	31.25%	32.84%	33.02%	31.42%	23.58%	19.57%
Profit Margin	26.53%	27.91%	29.38%	26.45%	18.80%	16.00%
Free Cash Flow Margin	10.10%	12.80%	6.36%	10.65%	9.43%	3.87%
EBITDA	1,319	1,327	999.36	713.25	403.23	260.33
EBITDA Margin	34.52%	35.92%	35.47%	33.96%	26.41%	22.99%
D&A For EBITDA	124.98	113.79	69.03	53.37	43.17	38.69
EBIT	1,194	1,214	930.33	659.88	360.06	221.64
EBIT Margin	31.25%	32.84%	33.02%	31.42%	23.58%	19.57%
Effective Tax Rate	11.49%	12.26%	11.11%	13.30%	19.36%	15.83%
Revenue as Reported	3,696	3,696	2,817	2,100	1,527	1,132
Advertising Expenses	-	-	-	-	2.94	5.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.